Clinical Trial Update: A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL [Phase 2]

View source ↗

Summary

Phase 2 trial of idelalisib plus rituximab in elderly patients with untreated CLL or SLL; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)
• Rituximab (rituximab)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Status: TERMINATED | Results posted: 2017-05-22